Pfizer/Lilly non-opioid pain drug shows more positive results

pharmaphorum | April 23, 2019

Pfizer/Lilly non-opioid pain drug shows more positive results
Results from a new study of Pfizer and Lilly’s non-opioid pain drug tanezumab have shown that it can be effective in osteoarthritis in higher doses, but lower doses remain ineffective and the drug had more adverse safety events than its comparators. The objective of the study was to compare the long-term joint safety and 16-week efficacy of tanezumab relative to nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with moderate-to-severe osteoarthritis (OA) of the hip or knee.
The tanezumab 5 mg treatment arm met two of the three co-primary efficacy endpoints, demonstrating a statistically significant improvement in pain and physical function compared to NSAIDs at the 16-week analysis, while patients’ overall assessment of their OA was not statistically different than NSAIDs.

Spotlight

Coordinated care recognizes that cancer is a complex disease, from the doctor’s appointments, medications, and treatments involved, to the support and follow-up required, and the questions patients need to be answered. This comprehensive, well-orchestrated care model is designed to ensure that patients’ medical needs are met in a seamless fashion. Care managers are at the heart of this model.

Spotlight

Coordinated care recognizes that cancer is a complex disease, from the doctor’s appointments, medications, and treatments involved, to the support and follow-up required, and the questions patients need to be answered. This comprehensive, well-orchestrated care model is designed to ensure that patients’ medical needs are met in a seamless fashion. Care managers are at the heart of this model.

Related News

PHARMA TECH

Saama Launches Active Safety Analytics for Pharma (ASAP), Co-built With Gilead to Transform Safety Surveillance

Saama Technologies, Inc. | October 27, 2020

Saama Technologies, Inc. (“Saama”), the AI clinical analytics platform company, announced today the launch of the new Active Safety Analytics for Pharma (ASAP) product. ASAP is the first validated pharmacovigilance solution to leverage the U.S. Food and Drug Administration’s (FDA) Sentinel Common Data Model and the TreeScan methodology for detecting safety signals. ASAP was co-built with Gilead Sciences, a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Saama and Gilead partnered to develop ASAP, with scientific advice from the Reagan-Udall Foundation for the FDA, and accelerate the life sciences industry’s paradigm shift to adopt active safety analytics.

Read More

PHARMACY MARKET

Fusion Pharmaceuticals and TRIUMF Announce Expanded R&D Collaboration for Actinium Supply Production

Fusion Pharmaceuticals Inc. | August 13, 2021

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, and TRIUMF, Canada's particle accelerator centre, today announced that the companies have entered into the next phase of their collaboration agreement for the development, production, and supply of actinium-225. Fusion will provide to TRIUMF funding to further develop technology to produce actinium-225 and in return Fusion will have rights, including preferred access and pricing, to the resulting alpha-emitting medical isotope. "As we advance our growing pipeline of actinium-based targeted alpha therapies (TATs), we are focused on expanding our manufacturing capabilities and continuing to proactively address and prioritize actinium supply. This supports our strategic plans to develop differentiated radiopharmaceuticals to treat a broad range of cancers with high unmet medical need," said Fusion Chief Executive Officer John Valliant, Ph.D. "We are excited to expand our collaborative relationship with TRIUMF, a leader in isotope production, marking an important step to further expand actinium-225 production and supply." "Through its TAT platform technology, Fusion has the opportunity to unlock the full potential of actinium, an alpha-emitting isotope with the ability to deliver a potent, highly localized payload to cancer cells, " said TRIUMF Innovations CEO, Kathryn Hayashi. "With this next phase, we are solidifying our partnership with a premier developer of innovative actinium radiopharmaceuticals to deepen TRIUMF's leadership position in isotope production and impact the cancer treatment landscape." TRIUMF Director and CEO, Nigel Smith, Ph.D. added, "This marks an important milestone in the existing collaboration between Fusion and TRIUMF. Our partnership is generating new ideas and innovations that validate the important role TRIUMF has at the forefront of the global medical isotope ecosystem. Together TRIUMF and Fusion are laying the groundwork for major breakthroughs that will benefit the lives of countless patients around the world." In December 2020, Fusion and TRIUMF entered a collaboration and supply agreement to develop, produce and procure the supply of actinium-225 to Fusion. As part of this agreement, Fusion will continue its investment of up to $25 million (CAD) in TRIUMF to advance technology and processes for actinium-225 production. About Fusion Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear™ linker technology, Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3); and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion recently entered into an agreement with Hamilton, Ontario-based McMaster University to build a 27,000 square foot current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs. About TRIUMF TRIUMF is Canada's particle accelerator centre. The lab is a hub for discovery and innovation, inspired by a half-century of ingenuity in answering some of nature's most challenging questions. From the hunt for the smallest particles in the universe to the development of new technologies, TRIUMF is pushing frontiers in research, while training the next generation of leaders in science, medicine, and industry.

Read More

PHARMA TECH

Iktos Announces Deployment of their AI for Drug Design Software Makya™ by Chiesi Group

Iktos and Chiesi Group | December 03, 2021

ktos, a company specialized in Artificial Intelligence for new drug design today announced collaboration agreement in AI for new drug design with Chiesi Group, the international research-focused pharmaceutical and healthcare. Under the agreement, Iktos’s de novo generative design software Makya™ will be used by Chiesi scientists to facilitate rapid and cost-effective design of novel compounds and accelerate hit-to-lead/lead optimisation for undisclosed Chiesi’s drug discovery programmes. Iktos has released Makya™, a generative AI-driven de novo design software for Multi-Parametric Optimization available either as a SaaS platform or for implementation on customer premises or in the customer’s Virtual Private Cloud. Makya’s user-friendly interface enables it to be used by medicinal or computational chemists. Makya™ can also be operated as a Python package through a Jupyter notebook interface. Iktos’ AI technology, based on deep generative models, helps bring speed and efficiency to the drug discovery process, by automatically designing virtual novel molecules that have desired activities for treating a given disease. This tackles one of the key challenges in drug design: rapid identification of molecules which simultaneously satisfy multiple bioactivity and drug-like criteria for drug discovery and development. “Licensing Makya is another step Chiesi wanted to complete in digitalization of R&D and in particular in drug discovery. The possibility of applying cutting edge AI technology relying on our internal expertise and historical data to drug design is very appealing. We think this emerging technology will become soon part of the compound design toolkit for all medicinal chemists, to facilitate their work aimed at identifying the right molecule”. Maurizio Civelli, Head of Global Research and Pre-Clinical Development Area of Chiesi Group “We are proud to work with Chiesi Farmaceutici, one of the top 50 pharmaceutical companies in the world, and to have their scientists use our software in their early discovery programs”, said Yann Gaston-Mathé, Co-founder and CEO of Iktos. “It is our ultimate goal to put our technology in the hands of drug discovery scientists, who have deep knowledge and understanding of their discovery programs. By combining their drug discovery expertise with our algorithmic and data science know-how and experience derived from the many collaborations we have established to date, we believe that the promise of AI to dramatically improve drug discovery will have a better chance to be realized and impact therapeutic development”. About Iktos Incorporated in October 2016, Iktos is a start-up company specializing in the development of artificial intelligence solutions applied to chemical research, more specifically medicinal chemistry and new drug design. Iktos is developing a proprietary and innovative solution based on deep learning generative models, which enables, using existing data, the design of molecules that are optimized in silico to meet all the success criteria of a small molecule discovery project. The use of Iktos technology enables major productivity gains in upstream pharmaceutical R&D. Iktos offers its technology both as professional services and as a SaaS software platform, Makya™. Iktos is also developing Spaya™, a synthesis planning software based upon Iktos’s proprietary AI technology for retrosynthesis. About Chiesi Group Based in Parma, Italy, Chiesi is an international research-focused pharmaceutical and healthcare group with over 85 years’ experience, operating in 30 countries with more than 6,000 employees. To achieve its mission of improving people’s quality of life by acting responsibly towards society and the environment, the Group researches, develops and markets innovative therapeutic solutions in its three focus areas: AIR (products and services that promote respiration, from new-born to adult populations), RARE and CARE. The Group’s Research and Development centre is based in Parma and works alongside six other important research and development hubs in France, the U.S., Canada, China, the UK and Sweden to pursue its pre-clinical, clinical and regulatory programmes. In 2018 Chiesi changed its legal status to Benefit Corporation, according to the law in Italy, the USA and, more recently, in France, by incorporating common benefit objectives into its bylaws, to generate value for its business, for the society and the environment. Since 2019, Chiesi has been the world’s largest B Corp certified pharmaceutical group. B Corps are global leaders committed to using business as a force for good. Moreover, as a Benefit Corporation, Chiesi Farmaceutici S.p.A. is required by law to report annually in a transparent way about its progress in achieving the common benefits objectives it has incorporated. The Group is committed to becoming carbon neutral by the end of 2035.

Read More